Dicot Pharma announces last day of trading in BTU and first day of trading for warrants series TO 6

Uppsala, Sweden, September 9, 2024. Dicot Pharma AB ("Dicot Pharma") announces that the rights issue that ended on August 27, 2024, will be registered with the Swedish Companies Registration Office this week and paid subscribed units (BTU) will be replaced with shares and warrants of series TO6. The last day of trading in BTU is September 11, 2024, and the stop date at Euroclear is September 13, 2024. The new shares and warrants series of TO 6 are expected to be booked into each shareholder's VP account/custody account on September 17, 2024. The first day of trading in warrants series of TO 6 is expected to be September 17, 2024.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com 

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Spotlight Stock Market and has approximately 6,500 shareholders. For more information, please visit www.dicotpharma.com.